Mortality at maximal · people with primary biliary cholangitis
It is very uncertain whether ciclosporin changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete response · patients with cutaneous disease in systemic lupus erythematosus
Oral ciclosporin showed no clear difference in primary outcome: complete clinical response compared with oral azathioprine (low certainty).
1 finding from 1 review
Primary outcome: partial clinical response · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral ciclosporin showed no clear difference in adverse events: severe compared with oral azathioprine (low certainty).
1 finding from 1 review
Adverse events: minor (hirsutism) · patients with cutaneous disease in systemic lupus erythematosus
Oral ciclosporin may leads to higher adverse events: minor (hirsutism) compared with oral azathioprine (low certainty).
1 finding from 1 review
HRQOL Ocular Surface Disease Index (scale 0 to 100, 100 worst) · Participants with ocular rosacea
1 finding from 1 review
Participant‐assessed improvement in rosacea severity ‐ not measured · Participants with ocular rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Proportion of participants with adverse event · Participants with ocular rosacea
Ciclosporin ophthalmic emulsion 0.05% showed no clear difference in proportion of participants with adverse event compared with artificial tears (low certainty).
1 finding from 1 review
Physician‐assessed improvement in rosacea severity Schirmer score · Participants with ocular rosacea
1 finding from 1 review
Assessment of erythema or telangiectasia ‐ not measured · Participants with ocular rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Lesion count ‐ not measured · Participants with ocular rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Time needed until improvement of the skin lesions · Participants with ocular rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Duration of remission ‐ not measured · Participants with ocular rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Ciclosporin · people with chronic plaque psoriasis
It is very uncertain whether any systemic treatment changes ciclosporin compared with placebo (very low certainty).
2 findings from 1 review